Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The placebo effect in asthma drug therapy trials: A meta-analysis
Autore:
Joyce, DP; Jackevicius, C; Chapman, KR; McIvor, RA; Kesten, S;
Indirizzi:
Univ Toronto, St Michaels Hosp, Family Practice Unit, Toronto, ON M5B 1W8,Canada Univ Toronto Toronto ON Canada M5B 1W8 e Unit, Toronto, ON M5B 1W8,Canada
Titolo Testata:
JOURNAL OF ASTHMA
fascicolo: 4, volume: 37, anno: 2000,
pagine: 303 - 318
SICI:
0277-0903(2000)37:4<303:TPEIAD>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
STEROID-DEPENDENT ASTHMA; TO-MODERATE ASTHMA; PEAK EXPIRATORY FLOW; DOUBLE-BLIND TRIAL; NEDOCROMIL SODIUM; INHALED CORTICOSTEROIDS; INDIVIDUAL PATIENTS; NOCTURNAL SYMPTOMS; ULCERATIVE-COLITIS; RANDOMIZED TRIALS;
Keywords:
placebo effect; asthma; drug therapy; meta-analysis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
60
Recensione:
Indirizzi per estratti:
Indirizzo: Kesten, S 900 Ridgebury Rd, Ridgefield, CT 06877 USA 900 Ridgebury Rd Ridgefield CT USA 06877 dgefield, CT 06877 USA
Citazione:
D.P. Joyce et al., "The placebo effect in asthma drug therapy trials: A meta-analysis", J ASTHMA, 37(4), 2000, pp. 303-318

Abstract

A meta-analysis of randomized controlled asthma drug therapy trials published in the English literature from January 1991 to June 1995 was performed to estimate the magnitude and direction of the placebo effect in stable ambulatory asthmatic patients. Among placebo groups, the mean absolute increase in forced expiratory volume in 1 sec (FEV1), weighted for sample size andvariance, was 0.11 L/min, and the mean percent increase in FEV1 was 4.81%. The corresponding placebo group changes in peak expiratory flow (PEF) werein an opposite direction to those of FEV1; there was a mean absolute decrease of 2.24 L/min, and a mean percent decrease of 4.21%. Changes for activetreatment groups were greater in magnitude. However, there were no statistically significant differences in mean changes comparing the placebo groupsto the treatment groups, for any of the outcome measures. Mean increases in PEF and FEV, exceeded 10% in 5 of 33 placebo groups, as compared to 13 of33 active treatment, groups. In conclusion, in well-designed long-term drug. therapy studies in stable asthmatics the pooled placebo effect is small but measurable, with FEV1 and PET showing different directions of response. Moreover, a modest number of patients receiving placebo have changes in pulmonary function that might be interpreted as clinically significant.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 13:32:21